Lobe Sciences Announces Private Placement for Corporate Funding

Lobe Sciences Ltd., a biopharmaceutical company based in Vancouver, announced a non-brokered private placement totaling up to $341,425 CAD. The offering comprises 8,535,625 common shares priced at $0.04 per share. The proceeds are designated for general corporate purposes, including working capital.

The issued securities will be under a statutory four-month and one-day hold period. The securities are not registered under the U.S. Securities Act of 1933, thus limiting their sale in the United States without registration or an exemption.

Forward-looking statements in the release highlight anticipated approvals and use of proceeds but acknowledge risks and uncertainties. These include potential challenges in completing the offering as planned and using the proceeds as intended.